TABLE 1.
Baseline table: patient and tumor characteristics
| n | % of total study population | |
|---|---|---|
| Total study population | 27 275 | 100% |
| Male sex | 15 270 | 56% |
| Age in years at diagnosis | ||
| Mean (±SD) | 68.6 (±11.7) | |
| Median (IQR) | 69.0 (61.0‐77.0) | |
| Categorical: | ||
| 0‐49 | 1723 | 6% |
| 50‐59 | 4087 | 15% |
| 60‐69 | 8097 | 30% |
| 70‐79 | 8198 | 30% |
| 80+ | 5170 | 19% |
| WHO performance status before start of treatment a | ||
| 0‐1 | 2643 | 43.4% |
| 2 | 369 | 6.1% |
| 3‐4 | 166 | 2.7% |
| Missing | 2912 | 47.8% |
| Primary tumor site | ||
| Right‐sided colon | 9649 | 35% |
| Left‐sided colon | 9021 | 33% |
| Rectal | 7540 | 28% |
| Location not specified or overlapping parts of colon | 1065 | 4% |
| >1 Primary tumor | 232 | 0.9% |
| Morphology | ||
| No pathologic diagnosis | 1578 | 6% |
| Adenocarcinoma | 22 518 | 83% |
| Mucinous adenocarcinoma | 2299 | 8% |
| Signet ring cell carcinoma | 610 | 2% |
| Other | 270 | 1% |
| Molecular pathology a | ||
| BRAF mutation | 197 | 3.2% |
| BRAF wildtype | 1121 | 18.4% |
| BRAF status unavailable | 4772 | 78.4% |
| RAS mutation | 794 | 13.0% |
| RAS wildtype | 846 | 13.9% |
| RAS status unavailable | 4450 | 73.1% |
| MSI | 89 | 1.5% |
| MSS | 1382 | 22.7% |
| MS status unavailable | 4619 | 75.8% |
| Number of metastatic sites at diagnosis | ||
| 1 organ | 16 800 | 61.6% |
| 2 organs | 7379 | 27.1% |
| 3 organs | 2441 | 8.9% |
| >3 organs | 655 | 2.4% |
| Localization metastases at diagnosis | ||
| Liver | 20 390 | 74.8% |
| Liver‐only | 11 657 | 42.7% |
| Lung | 6470 | 23.7% |
| Lung‐only | 1271 | 4.7% |
| Peritoneal | 6101 | 22.4% |
| Peritoneal‐only | 2422 | 8.9% |
| Bone | 934 | 3.4% |
| Brain | 190 | 0.7% |
Abbreviations: IQR, interquartile range; MS, microsatellite, MSI, microsatellite instable; MSS, microsatellite stable.
a
Available as of incidence year 2015. Calculated percentages are the proportion of the total population diagnosed in 2015 and 2016, see Table 2 for these numbers.